VICTORION-INITIATE supports early inclisiran treatment in ASCVD LIBerate-HR: Lerodalcibep reduces LDL-C in high and very high risk CVD US patients missing out on bempedoic acid Evolocumab benefits in patients with autoimmune and inflammatory diseases CLEAR Outcomes confirms bempedoic acid benefits for recurrent CV events PCSK9i access remains challenging in USA

PCSK9 Forum Inhibitors and Health Economics

Posted on 18 March 2014 |

The value of PCSK9 inhibition in very high risk patients is a Hot Topic in the light of recent data from the ODYSSEY OUTCOMES Economics Study. How do these data relate to the current clinical pathway used in the European setting?

PCSK9 Forum Editor Professor Anthony Wierzbicki (Guys and St. Thomas’ Hospital London, UK) puts the results in context.
Watch the video

Perspective on the ODYSSEY OUTCOMES Economic Study
Watch the video

PCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment?
Watch the video

Related content

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters